Physiological Root Resorption of Deciduous Teeth: An ATR-FTIR Approach.

: The study exploited, for the first time, Attenuated Total Reflectance-Fourier Transform-InfraRed (ATR-FTIR) spectroscopy on human dental pulps at different timings of root resorption (RR) to deepen the biological mechanisms occurring in deciduous teeth (De) during their replacement with permanent ones. : N:36 dental pulps from sound De were divided into the following: G0 (no RR); G1 (RR less than 1/3 of root length); G2 (RR not exceeding 2/3 of root length); and G3 (RR more than 2/3 of root length). Samples were analyzed by ATR-FTIR, and the spectral data were submitted to univariate (One-way ANOVA and Tukey's multiple comparison tests; statistical significance set at < 0.

Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution.

Introduction: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy and tolerability, we conducted a retrospective analysis of its first-line treatment outcomes.

Methods: We included patients with unresectable, locally advanced, or metastatic BTC treated with cisplatin, gemcitabine, plus durvalumab.

Intermediate hepatocellular carcinoma: new horizons and prospects for our patients.

Introduction: In recent years, significant progress has been made in treatment strategies for intermediate-stage hepatocellular carcinoma (HCC), which is a highly heterogeneous patient population requiring tailored therapies based on tumor characteristics.

Methods: We conducted a comprehensive review of treatment approaches for intermediate-stage HCC, highlighting the evolution of treatment options over time. While chemoembolization remains the standard therapy for many patients, it has advanced to include combinations with systemic therapies, known as combination therapy, which is becoming the new standard of care for this group.

Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.

Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries is sorafenib, due to the lack of reimbursement for other drugs. Several randomized trials are currently underway to clarify the best second-line therapy in patients with HCC.